Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824

Dan D. Vo, Robert M. Prins, Jonathan L. Begley, Timothy R. Donahue, Lilah F. Morris, Kevin W. Bruhn, Pilar De La Rocha, Meng Yin Yang, Stephen Mok, Hermes J. Garban, Noah Craft, James S. Economou, Francesco M. Marincola, Ena Wang, Antoni Ribas

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Tumors grow in the presence of antigen-specific T cells, suggesting the existence of intrinsic cancer cell escape mechanisms. We hypothesized that a histone deacetylase (HDAC) inhibitor could sensitize tumor cells to immunotherapy because this class of agents has been reported to increase tumor antigen expression and shift gene expression to a proapoptotic milieu in cancer cells. To test this question, we treated B16 murine melanoma with the combination of the HDAC inhibitor LAQ824 and the adoptive transfer of gp100 melanoma antigen-specific pmel-1 T cells. The combined therapy significantly improved antitumor activity through several mechanisms: (a)increase in MHC and tumor-associated antigen expression by tumor cells; (b)decrease in competing endogenous lymphocytes in recipient mice, resulting in a proliferative advantage for the adoptively transferred cells; and (c) improvement in the functional activity of the adoptively transferred lymphocytes. We confirmed the beneficial effects of this HDAC inhibitor as a sensitizer to immunotherapy in a different model of prophylactic prime-boost vaccination with the melanoma antigen tyrosinase-related protein 2, which also showed a significant improvement in antitumor activity against B16 melanoma. In conclusion, the HDAC inhibitor LAQ824 significantly enhances tumor immunotherapy through effects on target tumor cells as well as improving the antitumor activity of tumor antigen-specific lymphocytes.

Original languageEnglish
Pages (from-to)8693-8699
Number of pages7
JournalCancer Research
Volume69
Issue number22
DOIs
Publication statusPublished - 15 Nov 2009
Externally publishedYes

Fingerprint

Histone Deacetylase Inhibitors
Adoptive Transfer
T-Lymphocytes
Neoplasm Antigens
Neoplasms
Immunotherapy
Experimental Melanomas
Lymphocytes
gp100 Melanoma Antigen
Melanoma-Specific Antigens
LAQ824
Vaccination
Gene Expression
Antigens

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Vo, D. D., Prins, R. M., Begley, J. L., Donahue, T. R., Morris, L. F., Bruhn, K. W., ... Ribas, A. (2009). Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Research, 69(22), 8693-8699. https://doi.org/10.1158/0008-5472.CAN-09-1456

Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. / Vo, Dan D.; Prins, Robert M.; Begley, Jonathan L.; Donahue, Timothy R.; Morris, Lilah F.; Bruhn, Kevin W.; De La Rocha, Pilar; Yang, Meng Yin; Mok, Stephen; Garban, Hermes J.; Craft, Noah; Economou, James S.; Marincola, Francesco M.; Wang, Ena; Ribas, Antoni.

In: Cancer Research, Vol. 69, No. 22, 15.11.2009, p. 8693-8699.

Research output: Contribution to journalArticle

Vo, DD, Prins, RM, Begley, JL, Donahue, TR, Morris, LF, Bruhn, KW, De La Rocha, P, Yang, MY, Mok, S, Garban, HJ, Craft, N, Economou, JS, Marincola, FM, Wang, E & Ribas, A 2009, 'Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824', Cancer Research, vol. 69, no. 22, pp. 8693-8699. https://doi.org/10.1158/0008-5472.CAN-09-1456
Vo, Dan D. ; Prins, Robert M. ; Begley, Jonathan L. ; Donahue, Timothy R. ; Morris, Lilah F. ; Bruhn, Kevin W. ; De La Rocha, Pilar ; Yang, Meng Yin ; Mok, Stephen ; Garban, Hermes J. ; Craft, Noah ; Economou, James S. ; Marincola, Francesco M. ; Wang, Ena ; Ribas, Antoni. / Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. In: Cancer Research. 2009 ; Vol. 69, No. 22. pp. 8693-8699.
@article{538033a1ee774c878c34d1bf3c801438,
title = "Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824",
abstract = "Tumors grow in the presence of antigen-specific T cells, suggesting the existence of intrinsic cancer cell escape mechanisms. We hypothesized that a histone deacetylase (HDAC) inhibitor could sensitize tumor cells to immunotherapy because this class of agents has been reported to increase tumor antigen expression and shift gene expression to a proapoptotic milieu in cancer cells. To test this question, we treated B16 murine melanoma with the combination of the HDAC inhibitor LAQ824 and the adoptive transfer of gp100 melanoma antigen-specific pmel-1 T cells. The combined therapy significantly improved antitumor activity through several mechanisms: (a)increase in MHC and tumor-associated antigen expression by tumor cells; (b)decrease in competing endogenous lymphocytes in recipient mice, resulting in a proliferative advantage for the adoptively transferred cells; and (c) improvement in the functional activity of the adoptively transferred lymphocytes. We confirmed the beneficial effects of this HDAC inhibitor as a sensitizer to immunotherapy in a different model of prophylactic prime-boost vaccination with the melanoma antigen tyrosinase-related protein 2, which also showed a significant improvement in antitumor activity against B16 melanoma. In conclusion, the HDAC inhibitor LAQ824 significantly enhances tumor immunotherapy through effects on target tumor cells as well as improving the antitumor activity of tumor antigen-specific lymphocytes.",
author = "Vo, {Dan D.} and Prins, {Robert M.} and Begley, {Jonathan L.} and Donahue, {Timothy R.} and Morris, {Lilah F.} and Bruhn, {Kevin W.} and {De La Rocha}, Pilar and Yang, {Meng Yin} and Stephen Mok and Garban, {Hermes J.} and Noah Craft and Economou, {James S.} and Marincola, {Francesco M.} and Ena Wang and Antoni Ribas",
year = "2009",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-09-1456",
language = "English",
volume = "69",
pages = "8693--8699",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824

AU - Vo, Dan D.

AU - Prins, Robert M.

AU - Begley, Jonathan L.

AU - Donahue, Timothy R.

AU - Morris, Lilah F.

AU - Bruhn, Kevin W.

AU - De La Rocha, Pilar

AU - Yang, Meng Yin

AU - Mok, Stephen

AU - Garban, Hermes J.

AU - Craft, Noah

AU - Economou, James S.

AU - Marincola, Francesco M.

AU - Wang, Ena

AU - Ribas, Antoni

PY - 2009/11/15

Y1 - 2009/11/15

N2 - Tumors grow in the presence of antigen-specific T cells, suggesting the existence of intrinsic cancer cell escape mechanisms. We hypothesized that a histone deacetylase (HDAC) inhibitor could sensitize tumor cells to immunotherapy because this class of agents has been reported to increase tumor antigen expression and shift gene expression to a proapoptotic milieu in cancer cells. To test this question, we treated B16 murine melanoma with the combination of the HDAC inhibitor LAQ824 and the adoptive transfer of gp100 melanoma antigen-specific pmel-1 T cells. The combined therapy significantly improved antitumor activity through several mechanisms: (a)increase in MHC and tumor-associated antigen expression by tumor cells; (b)decrease in competing endogenous lymphocytes in recipient mice, resulting in a proliferative advantage for the adoptively transferred cells; and (c) improvement in the functional activity of the adoptively transferred lymphocytes. We confirmed the beneficial effects of this HDAC inhibitor as a sensitizer to immunotherapy in a different model of prophylactic prime-boost vaccination with the melanoma antigen tyrosinase-related protein 2, which also showed a significant improvement in antitumor activity against B16 melanoma. In conclusion, the HDAC inhibitor LAQ824 significantly enhances tumor immunotherapy through effects on target tumor cells as well as improving the antitumor activity of tumor antigen-specific lymphocytes.

AB - Tumors grow in the presence of antigen-specific T cells, suggesting the existence of intrinsic cancer cell escape mechanisms. We hypothesized that a histone deacetylase (HDAC) inhibitor could sensitize tumor cells to immunotherapy because this class of agents has been reported to increase tumor antigen expression and shift gene expression to a proapoptotic milieu in cancer cells. To test this question, we treated B16 murine melanoma with the combination of the HDAC inhibitor LAQ824 and the adoptive transfer of gp100 melanoma antigen-specific pmel-1 T cells. The combined therapy significantly improved antitumor activity through several mechanisms: (a)increase in MHC and tumor-associated antigen expression by tumor cells; (b)decrease in competing endogenous lymphocytes in recipient mice, resulting in a proliferative advantage for the adoptively transferred cells; and (c) improvement in the functional activity of the adoptively transferred lymphocytes. We confirmed the beneficial effects of this HDAC inhibitor as a sensitizer to immunotherapy in a different model of prophylactic prime-boost vaccination with the melanoma antigen tyrosinase-related protein 2, which also showed a significant improvement in antitumor activity against B16 melanoma. In conclusion, the HDAC inhibitor LAQ824 significantly enhances tumor immunotherapy through effects on target tumor cells as well as improving the antitumor activity of tumor antigen-specific lymphocytes.

UR - http://www.scopus.com/inward/record.url?scp=72249084921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72249084921&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-1456

DO - 10.1158/0008-5472.CAN-09-1456

M3 - Article

C2 - 19861533

AN - SCOPUS:72249084921

VL - 69

SP - 8693

EP - 8699

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 22

ER -